Exploring the Therapeutic Potential of the Leaderless Enterocins K1 and EJ97 in the Treatment of Vancomycin-Resistant Enterococcal Infection

Ingvild Reinseth¹, Hanne H. Tønnesen², Harald Carlsen¹ and Dzung B. Diep¹*

¹ Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway, ² Section of Pharmaceutics and Social Pharmacy, Department of Pharmacy, University of Oslo, Blindern, Oslo, Norway

The membrane-bound protease Eep is an important virulence factor in pathogenic enterococci. The protein is involved in stress response via the RIP pathway which is crucial for pathogenic enterococci to evade host immune attacks during infection. Eep serves also as a receptor for the bacteriocins enterocin K1 and enterocin EJ97. The bacteriocins kill Enterococcus faecium and E. faecalis, respectively, and their antibiotic resistant derivatives including vancomycin resistant enterococci (VRE). This functional duality of Eep makes these two enterocins very promising as options in the prospective treatment of enterococcal infections because wildtype enterococcal cells (with an intact Eep) are sensitive to the bacteriocins while bacteriocin-resistant-mutants (without a functional Eep) become less virulent. As a first step to explore their therapeutic potential in the treatment of systemic enterococcal infections, we investigated the compatibility of the bacteriocins with human blood, and the phenotypic changes of eep-mutants toward different stress conditions. We found that the bacteriocins were compatible with blood, as they did not cause haemolysis and that the bacteriocins retained most of their antibacterial effect when incubated in blood. The bacteriocins were autoclavable which is a crucial criterium for the development of parenteral administration. Eep-mutants, which became resistant to the bacteriocin were, as expected, less capable to withstand stress conditions such as exposure to lysozyme and desiccation. Further, their ability to chain, a trait implicated in niche adaptation as well as being necessary for genetic transfer via conjugation, was also severely affected. Together, these results indicate that the bacteriocins are promising for treatment of VRE infection.

Keywords: bacteriocin, VRE infection, Eep, enterococci, EntK1, EntEJ97

INTRODUCTION

Enterococci have emerged from the commensal enterococci to become a significant opportunistic pathogen and are especially dangerous for immunocompromised individuals (Lam et al., 2012; Rathnayake et al., 2012; Comerlato et al., 2013; Hefazi et al., 2016). They pose a serious problem not only due to their high innate resistance toward many antibiotics but also their well-developed ability to acquire resistance genes via genetic transfer, including resistance to vancomycin, a last
bacteriocins is therefore only possible through depletion of the receptor (by mutations).

Eep has been reported to be a virulence factor in several studies, through being involved in a stress response pathway that protects the bacteria from stress conditions encountered at an infection site, such as pH changes, reactive oxygen species and exposure to lysozyme (Le Jeune et al., 2010; Frank et al., 2013, 2015; Varahan et al., 2013). Eep, which is also called RseP, is part of a regulatory cascade, normally referred to as the regulated intramembrane proteolysis (RIP) pathway, that regulates the release of an extracytoplasmic sigma protein called SigV. SigV regulates stress responses in *E. faecalis* (Ovchinnikov et al., 2017). Therefore, resistance to the enterocins by lacking a functional Eep makes the bacteria less virulent, because they no longer have a functional stress-response and virulence factor—Eep.

To explore their therapeutic potential in VRE treatments, we present here a pre-clinical assessment of EntK1 and EntEJ97. The study includes the assessment of their compatibility with blood biomatrices, as well as an *in vitro* phenotypic characterisation of bacteriocin-induced *eep*-mutants. These mutants differ from previous works on Eep, because they are not bioengineered, but selected after exposure to the bacteriocin, hence mimicking an *in vivo* treatment situation.

**MATERIALS AND METHODS**

**Bacterial Strains, and Culture Conditions**

The bacterial strains are listed in Table 1. Unless otherwise specified the bacterial strains were grown in brain heart infusion (BHI) medium (Oxoid) at 37°C under aerobic conditions without shaking.

**Bacteriocins and Antimicrobial Assay**

Synthetic enterocins K1 and EJ97 peptides were purchased from Pepmuc Co., Ltd., China with 99% purity and solubilised to concentrations 1–10 mg/ml in Milli-Q water with 0.1% TFA. The peptides were stored at −20°C until use. The amino acid sequences of the bacteriocins are MLAKIKAMIKKFPNPYTLLAKKTTYEWKQKVQYGRYPWE RPVA and MKFKFNPTGTVKKTQYIEIAWFKNHGYYRPMWE IPRC for EntEJ97 and EntK1, respectively (Gálvez et al., 1998; Ovchinnikov et al., 2017). Bacteriocin activity was determined using a microtiter assay as previously described (Holo et al., 1991). MIC was determined as the minimum concentration that inhibited growth by at least 50% compared to control (without added bacteriocin) in 200 µl culture and the experiment was performed in three parallels.

**Haemolysis Assay**

To assess the haemolytic effect whole blood was drawn from two healthy human volunteers, pooled and distributed in 1 ml aliquots. The aliquots were spun down at 1,000 × g for 5 min at 4°C to separate erythrocytes from plasma. The erythrocytes were washed three times with saline (0.9% NaCl) and resuspended in 100 µl saline. The isolated erythrocytes were then added to samples of 900 µl of the testing agent,
as well as water for complete haemolysis and saline for the baseline, resulting in a 1 ml sample. SDS in saline was added as a control, since bacteriocins were solved in water. The experiment was repeated three times to allow for statistical analysis.

### Antibacterial Effect in Blood

To test whether the antibacterial effect of the bacteriocins was reduced in blood, an assay was performed where whole blood was collected from two healthy volunteers, with EDTA as an anticoagulant. Directly after blood sampling each bacteriocin was added to a concentration of 1mg/ml. In parallel controls of ampicillin and saline in blood as well as bacteriocin in saline were prepared. The samples were placed at 37°C, except for one of the bacteriocin in saline samples which was left at room temperature to ensure that the incubation at 37°C itself did not diminish bacteriocin activity. Samples were collected at specific time points and bacteriocin activity was determined using the standard MIC assay as previously described (Holo et al., 1991). The experiment was repeated three times and the error bars represent the standard deviation.

### Generation and Verification of E. faecalis and E. faecium Eep-Mutants

Bacteriocin resistant mutants were obtained by a spot-on-lawn assay, where liquid bacteriocin was spotted on a lawn of indicator cells, using 10µl of bacteriocin in concentrations 0.5–5 mg/ml. The plates were incubated at 30°C overnight and resistant colonies were selected from the inhibition zones and re-streaked on new plates for isolated colonies. Pure cultures were made and stored in 15% glycerol at −80°C. The eep gene was PCR amplified and sequenced with specific primers: eep in E. faecium was amplified using primers Eepf4F + Eepf4R and sequenced using primers Eepf1R - Eepf6R and Eepf1F - Eepf6F. eep in E. faecalis was amplified using primers Eepfa1R + Eepf3F and sequenced using primers Eepfa1R - Eepfa3R, Eepf1R - Eepf3R and Eepfa1F - Eepf3F. All primers are listed in Table 2.

The samples were sent to GATC Biotech, Germany for sequencing. MIC of the resistant mutants was scored using a microtiter assay as previously described (Holo et al., 1991).

### Tolerance Assays

To test for lysozyme tolerance the wild type and mutant strains were grown over night and subjected to a standard MIC assay as previously described with twofold dilutions of lysozyme (Holo et al., 1991). In addition, a spot-on-lawn assay was performed with 10 µl 250 mg/ml lysozyme spotted on a lawn of cells.

To test for differences in desiccation survival between the eep-mutants and wildtype, a desiccation survival assay was performed as follows. Overnight culture was distributed in the first column of a 96-well microtiter plate, with 20 µl in each well. These plates were left to dry at room temperature in natural light. At specific time points samples were added fresh media and serial dilutions were made. From these dilutions, samples were plated,
incubated overnight and CFU was enumerated as a measure of desiccation survival.

Scanning Electron Microscopy (SEM)
Strains were inoculated in fresh BHI medium and grown at 37°C until OD$_{550}$ = 0.3. Strains were grown in duplicates where one was added 500 µl of 200 mg/ml lysozyme to a final concentration of 20 mg/ml, and the other was added 500 µl BHI. The strains were then mixed 1:1 with the fixation solution, 4% paraformaldehyde (w/v) + 5% glutaraldehyde (v/v) in 1× PBS and left at 4°C over night. The samples were then washed with 0.2 M CaCo buffer and dehydrated before analysis by SEM.

RESULTS

Antibacterial Effect of EntK1 and EntEJ97
EntK1 and EntEJ97 specifically target Eep in enterococci (Ovchinnikov et al., 2017). We wanted to compare the potency of these bacteriocins toward laboratory and nosocomial strains. As shown in Table 3, most of these strains were relatively sensitive to the bacteriocins, regardless whether they were of laboratory type or nosocomial type. Toward the E. faecium strains MIC varied from <0.048 to 0.78 µg/ml, with strains P21 and 42ACA-D6 0237 being the most sensitive (both with MIC less than 0.048 µg/ml) while E8159 being the least sensitive (with MIC of about 0.78 µg/ml). Toward the E. faecalis strains MIC varied from <0.048 to 25 µg/ml, with strains V583 and T6 being the most sensitive (both with MIC of less than 0.048 µg/ml) while E8150 being the least sensitive (with MIC of about 25 µg/ml). When examining the genome of V583 we identified a gene encoding the immunity protein of enterocin EntEJ97 (data not shown); the presence of this gene likely explains the resistance of V583 toward the bacteriocin.

Haemolytic Activity of the Bacteriocins in Blood
VRE cause a range of infections, such as endocarditis, meningitis, sepsis and urinary tract infections (O’Driscoll and Crank, 2015; Reinseth et al., 2020). To reach these infection sites the bacteriocin would need to be circulated systemically and interact with blood constituents without causing lysis of erythrocytes. The haemolytic effect of the bacteriocins was therefore evaluated. No obvious haemolysis in erythrocytes was observed at the concentrations tested (0.01, 0.1, and 1 mg/ml), which are much higher than the MICs for all tested strains (Figure 1). This result was also comparable to what was observed for ampicillin, which is an antibiotic used in intravenous antibacterial treatment. As saline (0.9% NaCl) was used to dissolve the bacteriocins, we wanted to rule out the possibility that saline could have had an isotonic effect thereby preventing haemolysis by the bacteriocins. To test this, we challenged the blood cells with 0.1% SDS dissolved in saline. As seen in Figure 1 haemolysis was evident in the SDS solution, but not in the saline solution alone, confirming that the isotonic effect of saline could not prevent the haemolysis caused by the bacteriocins.

### Table 2: Oligonucleotide primers.

| Primer | Oligonucleotide sequence (5’ to 3’) |
|--------|------------------------------------|
| Eepf1R | GACAGTTTGCTGTTTGTATTCCC            |
| Eepf2R | TGTCGATGATTGCTGTCATTTC             |
| Eepf3R | CTCCTTCTAATTATCCTGACG              |
| Eepf4R | ACGTACGTCTGATATTTCG                |
| Eepf5R | TTAAGTCGTGATATTTCGC                |
| Eepf6R | TCTTTAAGACATACAGTTT                |
| Eepf1F | CGAAAGCGTATATGTTGCTGCC             |
| Eepf2F | TAAAACCTGTATTTCATTGGG              |
| Eepf3F | GCTTTAAGCAGATATTGC                 |
| Eepf4F | GATATGAATAAACCGC                  |
| Eepf5F | GCTTAAGCCGAGATAGAT                 |
| Eepf6F | GATTCTGAAAGACGGCGA                 |
| Eepfa1R| TAGGCGAAGTGTAGTCAAGTCC             |
| Eepfa2R| TTTTCAAGAATCTTCATGT                |
| Eepfa3R| ATCTCTTTAGCCTTACGGG                |
| Eepfa1F| TTTCGATACATTCG                    |
| Eepfa2F| CTCTCGATCTTCATGGCC                |
| Eepfa3F| GGTTTTCTACATGCGTTTG                |

### Table 3: The minimal inhibitory concentration (MIC) of EntK1 and EntEJ97 against laboratory (L), nosocomial (N), and probiotic (B) strains of E. faecium and E. faecalis.

| E. faecium strain | MIC$_{µg/ml}$ of EntK1 |
|-------------------|-----------------------|
| P21 (L)           | <0.048                |
| LMGT 20705 (L)    | <0.048                |
| 42ACA-D6 0237 (L) | 0.19                  |
| E1469 (N)         | 0.39                  |
| E3160 (N)         | 0.39                  |
| E3449 (N)         | 0.39                  |
| E6072 (N)         | 0.19                  |
| E6094 (N)         | 0.39                  |
| E6856 (N)         | 0.39                  |
| E7195 (N)         | 0.39                  |
| E7422 (N)         | 0.19                  |
| E7660 (N)         | 0.39                  |
| E8150 (N)         | 0.78                  |

| E. faecalis strain | MIC$_{µg/ml}$ of EntEJ97 |
|-------------------|--------------------------|
| D6 (L)            | 0.39                     |
| OG11RF (L)        | 0.78                     |
| 62 (L)            | 1.56                     |
| Symbiotil (B)     | 0.39                     |
| MMH6941 (N)       | 0.39                     |
| V583 (N)          | >25                      |
| Merz96 (N)        | 0.78                     |
| T3 (N)            | 0.39                     |
| TX0104 (N)        | 0.39                     |
| HH22 (N)          | 1.56                     |
Compatibility of the bacteriocins with blood. Whole human blood was mixed with each bacteriocin in saline to a final concentration of 1, 0.1, and 0.01 mg/ml. The samples were incubated at 37°C before the erythrocytes were spun down and the supernatant was read at OD540. (A) Percentage of haemolysis after contact with EntK1, EntEJ97 and Ampicillin at 1, 0.1, and 0.01 mg/ml. (B) Visual haemolysis after contact with dH2O, 0.1% SDS in saline, saline, and 1 mg/ml EntK1, 1 mg/ml EntEJ97, and 1 mg/ml Ampicillin. Like dH2O 0.1% SDS showed complete haemolysis, while 1 mg/ml EntK1, 1 mg/ml EntEJ97, and 1 mg/ml Ampicillin, all in saline, did not cause haemolysis as judged from the lack of redness, an indication of haemolysis, in the supernatant, compared to saline.

Antibacterial Activity of the Bacteriocins in Blood

The bacteriocins investigated in the current work are hydrophobic, possibly implicating interaction with several blood constituents (Gálvez et al., 1998; Ovchinnikov et al., 2017). If this interaction sequesters or somehow disturbs the antimicrobial effect of the bacteriocins, the suitability of the bacteriocins as an intravenous treatment would be compromised. Therefore, the antimicrobial effect of the bacteriocins was tested after incubation in whole blood and plasma (Figure 2). In saline the MIC of EntK1 was 0.19 µg/ml, and when added to blood or plasma the MIC was increased fourfold, to 0.78 µg/ml. After 8 h of incubation at 37°C the MIC of EntK1 in saline stayed at the same level, as did the MIC of EntK1 in plasma, which was 0.78 µg/ml. The MIC of EntK1 in blood, however, increased to approximately 1.56 µg/ml. After 24 and 48 h of incubation, the MIC increased in all groups, but at the same proportional rate. The MIC of EntK1 at 48 h in saline was 0.39 µg/ml, EntK1 in plasma 1.56 µg/ml and EntK1 in blood 3.125 µg/ml, but the ratios between them were the same at all time points (2× higher in plasma than saline, and 2× higher in blood than plasma).

The same ratio pattern was also observed for EntEJ97, with MIC 0.39 µg/ml in saline, 0.78 µg/ml in plasma and 1.56 µg/ml in blood after 8 h. After 48 h the MIC increased to 0.78 µg/ml in saline, 1.56 µg/ml in plasma and 3.125 µg/ml in blood.

Ampicillin was used as a control as this antibiotic is in use as an intravenous treatment against bacterial infections (Hellinger et al., 1992). Interestingly it seemed to follow the same pattern as the bacteriocins in terms of losing effect over time, starting at MIC 1.56 µg/ml in blood and ending with MIC 12.5 µg/ml at 48 h incubation.

Samples of the antimicrobials in saline left at room temperature (22–25°C) was included to ensure that the variation seen was due to the effect of the biomatrices alone and not the temperature at 37°C. At all time points samples at room temperature mirrored, though with some minor variations, that of the corresponding samples at 37°C, confirming the stability of the bacteriocin at 37°C.

To summarise, the MIC of the bacteriocins in blood and plasma increased by 2× or 4× from 4 to 48 h indicating only a 2–4-fold decrease in bacteriocin activity over 44 h. In addition, the MIC of the bacteriocins in blood compared to saline was
FIGURE 3 | Effect of autoclaving on EntK1 and EntEJ97. Each bacteriocin was solved in MilliQ water with 0.1% TFA and then autoclaved. The antibacterial effect of EntK1 and EntEJ97 was then tested against two strains of \textit{E. faecium} and two strains of \textit{E. faecalis}, respectively, in a standard MIC assay. The resulting MIC values are comparable between the autoclaved and non-autoclaved samples, indicating that autoclaving did not affect the antimicrobial effect of the enterocins. Strains: 20705 is short for \textit{E. faecium} LMGT 20705; 0237 for \textit{E. faecium} 42 ACA-D6 0237; D6 for \textit{E. faecalis} D6; and MMH594 for \textit{E. faecalis} MMH594.

4× higher for EntK1 and 2× higher for EntEJ97. In comparison ampicillin appeared to follow the same pattern, loosing 4×–8× activity after 48 h incubation in similar conditions.

Bacteriocin Activity Is Resilient to Autoclaving

A pre-requisite for intravenous administration is complete sterility of the compound (Paese et al., 2017). The simplest manner to achieve this is through autoclaving. However, this can cause degradation of the compound and therefore be detrimental to the antibacterial effect. Also, if the compound is degraded into unknown constituents this may cause unintended interactions. Therefore, we exposed the bacteriocins to a standard autoclaving procedure. The results indicated that autoclaving had no detrimental effect on the bacteriocins as their antimicrobial activity was virtually the same before and after autoclaving (see Figure 3).

Bacteriocin-Resistant Mutants Have Mutations Within \textit{Eep}

When enterococcal cells were exposed to EntK1 or EntEJ97 in the spot-on-lawn assay, we frequently observed resistant colonies in the inhibition zones (see Figure 4). Cells derived from these colonies had high MIC values for the bacteriocin used in the test, mostly above 25 μg/ml for both EntK1 and EntEJ97, in a cross-resistant manner. As the membrane bound protein Eep is known to serve as the receptor for EntK1, EntEJ97, and other bacteriocins belonging to the same family (Ovchinnikov et al., 2017), we suspected that these resistant cells might have acquired deleterious mutations within the \textit{eep} gene. Random resistant cells were therefore collected and the \textit{eep} gene sequenced. As expected, all the mutants contained mutations within \textit{eep} which caused various outcomes, ranging from insertions to duplications and substitutions (see Table 4).

Phenotypic Changes in Resistant Mutants

Considering that \textit{E. faecium} is increasingly becoming more prevalent in medical conditions, and has higher levels of antibiotic resistance than \textit{E. faecalis} and that most previous research on \textit{eep}-mutants has only concerned \textit{E. faecalis}, we therefore considered it appropriate to focus further characterisation on \textit{E. faecium} (Frank et al., 2013, 2015; Varahan et al., 2013; Prematunge et al., 2016; Reinseth et al., 2020). As Eep is involved in stress response, the \textit{eep}-mutants were analysed as to how they would cope with different stress factors. Lysozyme is one of the first defences of the body against pathogens, and therefore a deficiency in lysozyme resistance

FIGURE 4 | Resistant colonies (white spots) occur in EntK1 and EntEJ97 inhibition zones. 10 μl of 1 mg/ml EntK1 (A) or EntEJ97 (B) was applied onto soft agar containing \textit{E. faecium} P21 (A) or \textit{E. faecalis} MMH594 (B). The plate was left overnight at 30°C for cell growth and inhibition of cells. Arrows indicate resistant colonies growing within the inhibition zones.
would reduce a pathogen's virulence capacity. Two wild type strains, one of laboratory origin (P21) and one of nosocomial origin (E7422), and their respective mutants, were tested in a lysozyme MIC assay. As seen in Table 5 both wild type strains tolerated more lysozyme than their mutants, i.e., the MIC values for the wildtype strains being 6–8-fold higher than for the mutant strains, 15.63 and 0.98–1.95 mg/ml, respectively.

Enterococci can survive on surfaces for extended periods of time (Cetinkaya et al., 2000). This ability promotes the ability of the bacteria for spreading in e.g., hospital environments. Considering the role of Eep in stress response we hypothesised that it may also be implicated in desiccation survival. To our knowledge there is no data on desiccation survival on E. faecium (or E. faecalis) strains. Before testing the eep-mutants, we wanted to examine how different wild type strains responded to desiccation. Interestingly, as seen in Figure 5 three phenotypes presented among the wild type strains: the first indicated a rapid deterioration of cells and complete death 7 days from desiccation induction, as seen with E. faecium E3160. The second showed slow decrease in cell number and complete death by day 69, as seen with E. faecium E6072. The third exemplified by E7195 persisted beyond day 69. No obvious coherence between strain origin (nosocomial or laboratory) and desiccation tolerance was found.

We therefore subjected selected strains that had long desiccation survival phenotypes, E. faecium P21 and E7422, with their corresponding mutant strains (P21c.ins7 and 7422c.522del), to the same desiccation survival assay. The wildtype strains persisted at least to day 55. Strikingly, the eep-mutant strains were severely affected as judged from the fact that no live cells were found in the samples of these mutants from day 4 of desiccation. This result can be exemplified with the wild type E. faecium P21 and its eep-mutant P21c.ins7 in Figure 6.

**Scanning Electron Microscopy Reveals Loss of Chaining in Eep-Mutants**

Chaining has been implicated in niche adaptation and genetic transfer by conjugation (Domenech et al., 2018; McKenney et al., 2019). Previously it has been shown that strains with a non-functional SigV, which is the Eep associated sigma factor, lose the ability to chain in E. faecalis (Varahan et al., 2013). We hypothesised that the same would be true for the E. faecium eep-mutants. SEM analysis was performed on P21 and E7422 wildtype and counterpart mutant strains (P21c.ins7 and 7422c.522del), with and without lysozyme stress. As expected, the wildtype strains had a diplococcal morphology when lysozyme was not present but formed chains when exposed to lysozyme. In contrast, the mutant strains were not able to chain when exposed to lysozyme. An example from this experiment is shown in Figure 7 for the wild type P21 and the mutant P21c.ins7.

**DISCUSSION**

Antimicrobial peptides have long been proposed as treatment options although traditionally they have not been sufficiently preclinically assessed. Among the arising and most serious multidrug resistant bacteria are the VRE.

### TABLE 4 | Strain specific mutations.

| Parent strain | Mutant strain and type of mutation | Gene position | Outcome |
|---------------|-----------------------------------|---------------|---------|
| **E. faecium** |                                   |               |         |
| P21           | P21c.ins7—transposon insertion    | 7             | Gene interruption |
| P21c.ins23    | P21c.ins23—transposon insertion  | 23            | Gene interruption |
| P21c.ins43    | P21c.ins43—transposon insertion  | 43            | Gene interruption |
| P21           | P21c.G716A—base substitution     | 716           | Early stop codon |
| E3160         | 3160c.535del—base deletion       | 535           | Early stop codon |
| E6856         | 6856c.ins104—transposon insertion| 104           | Gene interruption |
| E7195         | 7195c.ins68—transposon insertion | 68            | Gene interruption |
| E7422         | 7422c.G62A—base substitution     | 62            | Amino acid substitution |
| E7422         | 7422c.C64A—base substitution     | 64            | Amino acid substitution |
| E7422         | 7422c.522del—base deletion       | 522           | Early stop codon |
| **E. faecalis** |                                   |               |         |
| D6            | D6c.dup708—duplication           | 708           | Frame shift |
| T3            | T3c.del708—duplication          | 708           | Frame shift |
| TX0104        | TX0104c.G625A—base substitution | 625           | Early stop codon |

### TABLE 5 | Lysozyme MIC in wildtype (WT) and mutant (M) strains.

| E. faecium | Lysozyme MIC mg/ml |
|-----------|--------------------|
| P21 (WT)  | 15.63              |
| P21c.ins7 (M) | 0.98            |
| P21c.ins23 (M) | 0.98           |
| P21c.ins43 (M) | 0.98            |
| P21c.G716A (M) | 0.98           |
| E7422 (WT) | 15.63              |
| 7422c.C64A (M) | 1.95             |
| 7422c.522del (M) | 1.95           |
These bacteria are human commensals but are also optimally positioned for opportunistic infection, with significance in immunocompromised individuals. The bacteriocins EntK1 and EntEJ97 specifically target enterococci through the Eep protein in the bacterial membrane. Eep is a virulence factor and bacteria without Eep (i.e., *eep*-mutants) will therefore become less capable of responding to stress (e.g., immune responses in the human host) and consequently, also less capable of establishing infection. In this study we have shown that the enterocins are promising in preclinical evaluation. The bacteriocins had MIC values for different enterococcal strains ranging from 0.048 to 1.56 µg/ml, which is promising for reaching efficient treatment doses. However, several studies have reported caution when estimating therapeutic doses based on MIC values from *in vitro* settings (Levison and Levison, 2009; Wen et al., 2016). This should therefore be tested in a relevant *in vivo* model. The nosocomial strains did not consistently have higher MIC values than the laboratory strains, indicating that there was no obvious adaptation to EntK1/EntEJ97 resistance in strains isolated from infection sites. Both EntK1 and EntEJ97 were compatible with blood, as they did not cause haemolysis and only moderately decreased in antimicrobial effect, in an extent comparable to ampicillin, in human blood. The bacteriocins were autoclavable which is important to avoid bacterial contamination during drug formulation. *Eep*-mutants were less capable to withstand lysozyme and desiccation indicating that they had decreased fitness, hence likely also decreased virulence. The *eep*-mutants lost the ability to chain, further indicating loss of adaptation to stressful conditions.

An important goal of this study was to determine whether the bacteriocins were compatible with blood, which is required for the development of parenteral treatments (Paese et al., 2017). Most antimicrobial peptides are cationic and amphiphilic. Consequently, one of the main concerns with antimicrobial peptides are their ability to cause haemolysis, through positively charged amino acids binding to the negatively charged lipid bilayer. This binding can cause membrane disintegration and eventually erythrocyte-burst (Kumar et al., 2020). By analysis of the peptides with the haemolytic potential prediction programme HemoPred (Win et al., 2017), EntK1 is predicted to have haemolytic potential, while EntEJ97 is not. We have shown here that neither of the peptides are haemolytic up to a concentration of 1 mg/ml. The secondary structure of EntK1 consists of an α-helix from residue 8 to residue 25 (Ovchinnikov et al., 2017).
Hydrophobic residues in an α-helix increases a peptide’s probability of being haemolytic (Win et al., 2017). In the region predicted to be α-helical EntK1 has 10 hydrophobic residues out of 18. Specific motifs and residues are important for haemolytic capability, and although EntK1 is predicted to be haemolytic it does not have any of the reported motifs. In addition, only 11 out of 37 residues are reported as important for haemolysis (L, K, F, and W) (Chaudhary et al., 2016; Oddo and Hansen, 2017). EntEJ97 has a total of 44 amino acids. Of them 22 are hydrophobic amino acids and 12 were predicted important for haemolysis. To our knowledge no structural studies have been performed on EntEJ97. Altogether this indicates that even though these bacteriocins are hydrophobic, they are non-haemolytic up to 1 mg/ml concentration in experimental settings. The fact that the peptides have some hydrophobic properties means they have potential to bind to serum proteins. It is possible that this binding could interfere with the antibacterial effect of the bacteriocins, but it is also possible that the binding could aid drug distribution. Svenson et al. (2007) and Sivertsen et al. (2013, 2014) found in two independent studies that a range of antibacterial peptides associated with the two major plasma proteins human serum albumin (HSA) and alpha-1 acid glycoprotein. However, only binding to HSA reduced the antibacterial effect of the peptides. In our study we investigated whether incubation in blood decreases the antibacterial effect of the bacteriocins. We found that there was some decrease in antibacterial effect over time, but that the MIC was consistently 2–4 times higher in blood compared to saline, including for ampicillin as control. This reduction in activity could be attributed to HSA binding, although this is unlikely because previous research has shown that the concentration of HSA is higher in plasma than in blood. It is also possible that the bacteriocin was degraded by blood constituents (Svenson et al., 2007; Bottger et al., 2017; Harm et al., 2019). Previous work has found that the stability of peptides is greater in whole blood than in plasma and serum (Bottger et al., 2017). This does not correspond to our study where the MIC values of our bacteriocins were consistently higher in blood than in plasma. This difference could be due to the nature of the peptides per se. However, it is also tempting to attribute this discrepancy to the bacteriocin associating to erythrocytes and therefore some of the antibacterial effect being quenched by this association. The MIC values showed promise for in vivo treatment. The bacteriocins were resilient to autoclaving as expected. Bacteriocins are mainly heat stable (Nes et al., 2014), and several studies have investigated AMPs from other lactic acid bacteria producers and found that they were resilient to autoclaving (Jamuna and Jeevaratnam, 2004; Chang et al., 2018).

Several studies have reported the involvement of SigV and Eep in enterococcal virulence. SigV, an extracytoplasmic sigma factor, is involved in enterococcal resistance toward different environmental stresses such as heat and acids (Benachour et al., 2005). SigV is also involved in lysozyme resistance, and in the ability of E. faecalis to cause urinary tract and intravenous
infection in a murine model (Le Jeune et al., 2010). eep deletion-mutants were attenuated in an endocarditis rabbit model, and showed reduced kidney colonisation in a urinary tract infection model (Frank et al., 2012). The relationship between Eep and SigV was established by experiments that showed that an eep deletion mutant phenocopied a sigV deletion mutant in the resistance against heat, low pH and ethanol stress (Varahan et al., 2013). This, and similar studies of homologous systems in other species indicate that the Eep protein is involved in the breakdown of RsvV which is the anti-sigma factor to SigV (Benachour et al., 2013). Therefore, Eep likely controls the activation of the stress response that is transcribed from the sigV regulon. Several of these studies have proposed Eep and/or the SigV stress response as promising targets for antibacterial therapy (Le Jeune et al., 2010; Frank et al., 2013). Ovchinnikov et al. (2017) reported that in E. faecalis and E. faecium Eep is the receptor for EntK1 and EntEJ97, and that resistant mutants have a non-functional Eep protein. Most previous works on eep-mutants have been done with E. faecalis strains (Benachour et al., 2005; Le Jeune et al., 2010; Frank et al., 2012, 2013, 2015; Varahan et al., 2013). In this study we report eep-mutants of E. faecium. This opportunistic pathogen, although somewhat less virulent than E. faecalis, is more frequent in vancomycin resistance than E. faecalis and therefore becoming a major threat to public health (Comerlato et al., 2013; Kristich et al., 2014). E. faecalis is well-known for its lysozyme resistance, and although not well characterised there are some reports of lysozyme resistant E. faecium strains (Le Jeune et al., 2010; Kivanc et al., 2016). The eep-mutants of E. faecium in the present study showed an 8x reduction in lysozyme tolerance compared to the wild type strains. Lysozyme is a first line of defence in humans, important to reduce the load of invading microorganisms (Le Jeune et al., 2010). Our findings in E. faecium correlate well with previous findings that also report a reduction in lysozyme tolerance in eep or sigV mutants of E. faecalis (Benachour et al., 2005; Le Jeune et al., 2010).

Wild type enterococcal cells are extremely adapt to survival on surfaces and have been reported to persist for years. We report here that strains with mutations in eep have a dramatically decreased ability to survive desiccation. This is in line with a previous study which showed that the Eep-activated sigV-operon is overexpressed during exposure to starvation (Benachour et al., 2005). This finding is of utmost importance due to the spread of enterococci not only from biotic surfaces such as skin and hair but also from abiotic surfaces e.g., floors, ventilators and surgery equipment in hospitals. If the bacteriocin resistant eep-mutants are not able to survive on surfaces due to a failure in activating the appropriate stress response, treatments with the bacteriocins (e.g., as ingredients in wash or spray solution) could decrease enterococcal cells from surfaces and thereby limit this reservoir. However, this phenotype needs to be confirmed in more strains, and the possibility that other factors are causing the phenotype should be explored. Similarly E. faecalis switches from diplococci to long chain morphology, as a stress response upon exposure to bile salts (McKenney et al., 2019). Chaining has also been implicated in competence to exchange antibiotic resistance genes in other cocci (Domenech et al., 2018). This chaining adaptation has been reported to be faulty in eep-mutants of E. faecalis when exposed to lysozyme (Varahan et al., 2013). We found that the same was true for E. faecium, as its eep-mutants did not chain when exposed to lysozyme (see Figure 7). This is relevant for treatment considering that antimicrobial resistance can develop from repeated exposure in the gastrointestinal tract, and lysozyme is an important local innate defence (Dommett et al., 2005; Le Jeune et al., 2010). If the enterocin-treated enterococci (either being killed or become eep-mutants) are unable to adapt to the gastrointestinal environment, they can no longer persist and disseminate from there. As the gastrointestinal tract is an important reservoir for VRE infection in immunocompromised individuals, these results might be very useful when developing strategies to reduce risk of VRE in such medical conditions.

These results taken together could indicate that Eep is essential for enterococcal survival of several types of stressors commonly encountered in in vivo situations, and that bacteriocin-induced eep-mutants are likely less capable to establish infection. This, in addition to the lack of toxicity and compatibility with blood, makes the bacteriocins EntK1 and EntEJ97 ideal for treatment of VRE infections. However, this notion is valid only for the strains tested here, and future work should therefore investigate whether these traits are of general features for these two species and whether they are also applied to relevant in vivo models.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

IR designed and performed the experiments, analysed the data, and wrote the manuscript. HT and HC designed, analysed the data, and revised the manuscript. DD obtained funding, designed the experiments, and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was partly financed by the Research Council of Norway (project no. 275190). The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

ACKNOWLEDGMENTS

We thank Prof. Rob J. L. Willems (University Medical Center Utrecht, Utrecht, Netherlands) for providing us with E. faecium isolates from human infections.
REFERENCES

Benachour, A., Muller, C., Dabrowski-Coton, M., Le Breton, Y., Giard, J. C., Rince, A., et al. (2005). The Enterococcus faecalis sigV protein is an extractoplasmin function sigma factor contributing to survival following heat, acid, and ethanol treatments. J. Bacteriol. 187, 1022–1035. doi: 10.1128/jb.187.3.1022-1035.2005

Bottrup, R., Hoffmann, R., and Knappe, D. (2017). Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLoS One 12:e0178943. doi: 10.1371/journal.pone.0178943

Bourgogne, A., Garsin, A. D., Bing, X., Singh, K. V., Sillanpa, J., Yerrapragada, S., et al. (2008). Large scale variation in Enterococcus faecalis illustrated by the genome analysis of strain OGI150. Genome Biol. 9:R110.

Brede, D. A., Snipen, L. G., Ussery, D. W., Nederbragt, A. J., and Nes, I. F. (2010). Complete genome sequence of the commensal Enterococcus faecalis 62, isolated from a healthy Norwegian infant. J. Bacteriol. 193, 2377–2387. doi: 10.1128/jb.00183-11

Buetti, N., Wassleib, N., Rion, V., Senn, L., Gardiol, C., Widmer, A., et al. (2019). Emergence of vancomycin-resistant enterococci in Switzerland: a nation-wide survey. Antimicrob. Resist. Infect. Control. 8:16.

Cetinkaya, Y., Falk, P., and Mayhall, C. G. (2000). Vancomycin-resistant enterococci. Clin. Microbiol. Rev. 13, 686–707.

Chang, R., Lu, H., Li, M., Zhang, S., Xiong, L., and Sun, Q. (2018). Preparation and characterization of antimicrobial peptides for clinical application. Int. J. Mol. Sci. 20:5426. doi: 10.3390/ijms2015426

Harrington, S. M., Ross, T. L., Gebo, K. A., and Merz, W. G. (2004). Vancomycin resistance, esp, and strain relatedness: a 1-year study of Enterococcal bacteremia. J. Clin. Microbiol. 42, 5895–5898. doi: 10.1128/jcm.42.12.5895-5898.2004

Hefazi, M., Damlaj, M., Alkhateeb H. B., Partain, D. K., Patel, R., Razonable, R. R., et al. (2016). Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl. Infect. Dis. 18, 913–920. doi: 10.1111/tid.12612

Helling, W. C., Rouse, M. S., Rababdan, P. M., Henry, N. K., Steckelberg, J. M., and Wilson, W. R. (1992). Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci. Antimicrob. Agents Chemother. 36, 1277–1275. doi: 10.1128/aaac.36.6.1277-1275.

Herranz, C., Casaus, P., Muhkopadhyay, S., Martinez, J. M., Rodriguez, J. M., Nes, I. F., et al. (2001). Enterococcus faecium P21: a strain occurring naturally in dry-fermented sausages producing the class II bacteriocins enterocin A and enterocin B. Food Microbiol. 18, 115–131. doi: 10.1006/fmic.2000.0382

Holo, H., Nilssen, O., and Nes, I. F. (1991). Lactococcin A, a new bacteriocin from Lactococcus lactis subsp. cremoris: isolation and characterization of the protein and its gene. J. Bacteriol. 173, 3879–3887. doi: 10.1128/jb.173.12.3879-3887.1991

Huycke, M. C., Spiegel, C. A., and Gilmore, M. S. (1991). Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 35, 1626–1634. doi: 10.1128/aaac.35.8.1626

Jamuna, M., and Jeevaramnam, K. (2004). Isolation and partial characterization of bacteriocins from Pediococcus species. Appl. Microbiol. Biotechnol. 65, 433–439. doi: 10.1007/s00253-004-1576-8

Kivanc, S. A., Kivanc, M., and Yigit, T. (2016). Antibiotic susceptibility, antibacterial activity and characterisation of Enterococcus faecium strains isolated from breast milk. Exp. Ther. Med. 12, 1732–1740. doi: 10.3982/etm.2016.3545

Kristch, C. J., Rice, L. B., and Arias, C. A. (2014). “Enterococcal infection-treatment and antibiotic resistance,” in Enterococci: From Commensals to Leading Causes of Drug Resistant Infection, eds M. S. Gilmore, D. B. Clewell, Y. Ike, and N. Shankar (Boston: Massachusetts Eye and Ear Infirmary).

Kumar, V., Kumar, R., Agrawal, P., Patiyal, S., and Raghava, G. P. S. (2020). A method for predicting hemolytic potency of chemically modified peptides from its structure. Front. Pharmacol. 11:54.

Lam, M. M., Seemann, T., Bulach, D. M., Gladman, S. L., Chen, H., Haring, V., et al. (2012). Comparative analysis of the first complete Enterococcus faecium genome. J. Bacteriol. 194, 2334–2341. doi: 10.1128/jb.00259-12

Le Jeune, A., Torelli, R., Sanguinetti, M., Giard, J. C., Hartke, A., Auffray, Y., et al. (2010). The extracytoplasmic function sigma factor SigV plays a key role in the original model of lysosome resistance and virulence of Enterococcus faecalis. PLoS One 5:e9658. doi: 10.1371/journal.pone.009658

Levison, M. E., and Levison, J. H. (2009). Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect. Dis. Clin. North Am. 23, 791–815. doi: 10.1016/j.clinmicn.2009.06.008

Maekawa, S., Yoshioka, M., and Kumamoto, Y. (1992). Proposal of a new scheme for the serological typing of Enterococcus faecalis strains. Microb. Immunol. 36, 671–681. doi: 10.1111/j.1348-0421.1992.tb02070.x

McKenney, P. T., Yan, J., Vaubourgeix, J., Becattini, S., Lampen, N., Motzer, A., et al. (2019). Intestinal bile acids induce a morphotype switch in vancomycin-resistant enterococci that facilitates intestinal colonization. Cell Host Microbe 25, 695–705.e695.

Murray, B. E., and Mederski-Samaroj, B. (1983). Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J. Clin. Invest. 72, 1168–1171. doi: 10.1172/jci111042

Nes, I. F., Diep, D. B., and Ike, Y. (2014). “Enterococcal bacteriocins and antimicrobial proteins that contribute to niche control,” in Enterococci: From Commensals to Leading Causes of Drug Resistant Infection, eds M. S. Gilmore, D. B. Clewell, Y. Ike, and N. Shankar (Boston: Massachusetts Eye and Ear Infirmary).

Oddo, A., and Hansen, P. R. (2017). Hemolytic activity of antimicrobial peptides. Methods Mol. Biol. 1548, 427–435. doi: 10.1007/978-1-4939-6737-7_31
O’Driscoll, T., and Crank, C. W. (2015). Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. *Infect. Drug Resist.* 8, 217–230. doi: 10.2147/idr.s54125

Ovchinnikov, K. V., Kristiansen, P. E., Straume, D., Jensen, M. S., Aleksandrak-Piekarczyk, T., Nes, I. F., et al. (2017). The leaderless bacteriocin enterocin K1 is highly potent against *Enterococcus faecium*: a study on structure, target spectrum and receptor. *Front. Microbiol.* 8:774.

Ovchinnikov, K. V., Kristiansen, P. E., Uzelac, G., Topisirovic, L., Kojic, M., Nissen-Meyer, J., et al. (2014). Defining the structure and receptor binding domain of the leaderless bacteriocin LsbB. *J. Biol. Chem.* 289, 23838–23845. doi: 10.1074/jbc.m114.579698

Paese, K., Ortiz, M., Frank, L. A., Kulkamp-Guerreiro, I. C., Rolim, C. M., Barros, D. M., et al. (2017). Production of isotonic, sterile, and kinetically stable lipid-core nanocapsules for injectable administration. *AAPS PharmSciTech* 18, 212–223. doi: 10.1208/s12249-016-0499-3

Palmer, K. L., Carniol, K., Manson, J. M., Heiman, D., Shea, T., Young, S., et al. (2010). High-quality draft genome sequences of 28 *Enterococcus* sp. isolates. *J. Bacteriol.* 192, 2469–2470. doi: 10.1128/jb.00153-10

Patel, R., and Gallagher, J. C. (2015). Vancomycin-resistant enterococcal bacteremia pharmacotherapy. *Ann. Pharmacother.* 49, 69–85. doi: 10.1177/1060028014556879

Pidot, S. J., Gao, W., Buitjens, A. H., Monk, I. R., Guerillot, R., Carter, G. P., et al. (2018). Increasing tolerance of hospital *Enterococcus faecium* to handwash alcohols. *Sci. Transl. Med.* 10:452.

Pretamuteng, C., MacDougall, C., Johnstone, J., Adomako, K., Lam, F., Robertson, J., et al. (2016). VRE and VSE bacteremia outcomes in the era of effective VRE therapy: a systematic review and meta-analysis. *Infect. Control. Hosp. Epidemiol.* 37, 26–35. doi: 10.1017/ice.2015.228

Rathnayake, I. U., Hargreaves, M., and Huygens, F. (2012). Antibiotic resistance and virulence traits in clinical and environmental *Enterococcus faecalis* and *Enterococcus faecium* isolates. *Syst. Appl. Microbiol.* 35, 326–333. doi: 10.1016/j.syapm.2012.05.004

Reinseth, I. S., Ovchinnikov, K. V., Tonnesen, H. H., Carlsen, H., and Diep, D. B. (2020). The increasing issue of vancomycin-resistant enterococci and the bacteriocin solution. *Probiotics Antimicrob. Proteins* 12, 1203–1217. doi: 10.1007/s12602-019-09618-6

Rosko, A. E., Corriveau, M., Suwantarat, N., Arfons, L., Treasure, M., Parker, P., et al. (2014). Vancomycin-resistant enterococci infection: not just for the transplanted. *Leuk Lymphoma* 55, 1320–1325.

Sahm, D. F., Kissinger, J., Gilmore, M. S., Murray, P. R., Mulder, R., Soliday, J., et al. (1989). In vitro susceptibility studies of vancomycin-resistant *Enterococcus faecalis*. *Antimicrob. Agents Chemother.* 33, 1588–1591. doi: 10.1128/aac.33.9.1588

Simons, A., Alhanout, K., and Duval, R. E. (2020). Bacteriocins, antimicrobial peptides from bacterial origin: overview of their biology and their impact against multidrug-resistant bacteria. *Microorganisms* 8:639. doi: 10.3390/microorganisms8050639

Sivertsen, A., Brandsdal, B. O., Svendsen, J. S., Andersen, J. H., and Svenson, J. (2013). Short cationic antimicrobial peptides bind to human alpha-1 acid glycoprotein with no implications for the in vitro bioactivity. *J. Mol. Recognit.* 26, 461–469. doi: 10.1002/jmr.2288

Sivertsen, A., Isaksson, J., Leiros, H. K., Svenson, J., Svendsen, J. S., and Brandsdal, B. O. (2014). Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin. *BMC Struct. Biol.* 14:4. doi: 10.1186/1472-6807-14-4

Svenson, J., Brandsdal, B. O., Stensen, W., and Svenson, J. S. (2007). Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. *J. Med. Chem.* 50, 3334–3339. doi: 10.1021/jm0703542

The Nih Hmp Working Group, Peterson, J., Garges, S., Giovanni, M., McInnes, P., Wang, L., et al. (2009). The NIH human microbiome project. *Genome Res.* 19, 2317–2323.

Uzelac, G., Kojic, M., Lozo, J., Aleksandrak-Piekarczyk, T., Gabrielsen, C., Kristensen, T., et al. (2013). A Zn-dependent metallopeptidase is responsible for sensitivity to LsbB, a class II leaderless bacteriocin of *Lactococcus lactis* subsp. lactis BGMN1-5. *J. Bacteriol.* 195, 5614–5621. doi: 10.1128/jb.00859-13

Varahan, S., Iyer, V. S., Moore, W. T., and Hancock, L. E. (2013). Eep confers lysozyme resistance to *Enterococcus faecalis* via the activation of the extracytoplasmic function sigma factor SigV. *J. Bacteriol.* 195, 3125–3134. doi: 10.1128/jb.00291-13

Wen, X., Gehring, R., Stallbaumer, A., Riviere, J. E., and Volkova, V. V. (2016). Limitations of MIC as sole metric of pharmacodynamic response across the range of antimicrobial susceptibilities within a single bacterial species. *Sci. Rep.* 6:37907.

Win, T. S., Malik, A. A., Prachayasittikul, V., Wikberg, J. E. S., Nantasenamat, C., and Shoombuatong, W. (2017). HemoPred: a web server for predicting the hemolytic activity of peptides. *Future Med. Chem.* 9, 275–291. doi: 10.4155/fmc-2016-0188

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Reinseth, Tonnesen, Carlsen and Diep. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.